These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21838869)

  • 1. A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis.
    Kleemann R; Bureeva S; Perlina A; Kaput J; Verschuren L; Wielinga PY; Hurt-Camejo E; Nikolsky Y; van Ommen B; Kooistra T
    BMC Syst Biol; 2011 Aug; 5():125. PubMed ID: 21838869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
    Monetti M; Canavesi M; Camera M; Parente R; Paoletti R; Tremoli E; Corsini A; Bellosta S
    Pharmacol Res; 2007 May; 55(5):441-9. PubMed ID: 17350858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systems biology approaches to the study of cardiovascular drugs.
    Nikolsky Y; Kleemann R
    Methods Mol Biol; 2010; 662():221-43. PubMed ID: 20824474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy.
    Verschuren L; Radonjic M; Wielinga PY; Kelder T; Kooistra T; van Ommen B; Kleemann R
    Pharmacogenet Genomics; 2012 Dec; 22(12):837-45. PubMed ID: 23086299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
    Srivastava RA
    Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artesunate attenuated progression of atherosclerosis lesion formation alone or combined with rosuvastatin through inhibition of pro-inflammatory cytokines and pro-inflammatory chemokines.
    Jiang W; Cen Y; Song Y; Li P; Qin R; Liu C; Zhao Y; Zheng J; Zhou H
    Phytomedicine; 2016 Oct; 23(11):1259-66. PubMed ID: 27316397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques.
    Alaarg A; Zheng KH; van der Valk FM; da Silva AE; Versloot M; van Ufford LC; Schulte DM; Storm G; Metselaar JM; Stroes ES; Hamers AA
    Vascul Pharmacol; 2016 Jul; 82():51-9. PubMed ID: 27189780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
    Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM
    Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
    Martin PD; Dane AL; Schneck DW; Warwick MJ
    Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
    Olsson AG; McTaggart F; Raza A
    Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
    Wang JA; Chen WA; Wang Y; Zhang S; Bi H; Hong B; Luo Y; Daugherty A; Xie X
    Atherosclerosis; 2011 Jul; 217(1):90-6. PubMed ID: 21481872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions.
    Kei A; Liberopoulos E; Tellis C; Elisaf M; Tselepis A
    Lipids; 2013 Oct; 48(10):957-65. PubMed ID: 23949918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
    Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice.
    Enomoto S; Sata M; Fukuda D; Nakamura K; Nagai R
    Biomed Pharmacother; 2009 Jan; 63(1):19-26. PubMed ID: 18162361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models.
    Kleemann R; Verschuren L; Morrison M; Zadelaar S; van Erk MJ; Wielinga PY; Kooistra T
    Atherosclerosis; 2011 Sep; 218(1):44-52. PubMed ID: 21601209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of rosuvastatin on atherosclerosis lesions in apolipoprotein E knockout mice].
    Luo RN; Tao LJ; Zhou J; Wang R; Lu MM; Fu X
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Aug; 39(8):743-8. PubMed ID: 22169423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperlipidaemia with fenofibrate and related fibrates.
    Filippatos T; Milionis HJ
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1599-614. PubMed ID: 18808320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.